How country-specific should a country-specific cost-effectiveness analysis be?
Shelby D
SD
Reed
D054058:Acute Coronary Syndrome / Q000191:economics*; D000241:Adenosine / Q000031:analogs & derivatives* / Q000191:economics; D000925:Anticoagulants / Q000191:economics*; D001281:Atrial Fibrillation / Q000191:economics*; D001562:Benzimidazoles / Q000191:economics*; D000069604:Dabigatran; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000191:economics*; D000077486:Ticagrelor; D014859:Warfarin / Q000191:economics*; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000191:economics
D000925:Anticoagulants; D001562:Benzimidazoles; D010975:Platelet Aggregation Inhibitors; D015091:beta-Alanine; D014859:Warfarin; D000077486:Ticagrelor; D000069604:Dabigatran; D000241:Adenosine